Loading stock data…
AVTR
$8.05+0.06 (+0.75%)
Pre-Market$8.17+0.12 (+1.49%)· Last close May 5
Avantor, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Avantor, Inc. in the Healthcare sector is trading at $8.05. The stock is currently near its 52-week low of $7.26, remaining 27.9% below its 200-day moving average. Technical signals show neutral RSI of 42 and bullish MACD crossover, explaining why AVTR maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 42) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$8.05
Potential Upside
5%
Whystock Fair Value$8.45
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus13 analysts
Hold
Mean target$9.92+23.3%
Range$7.00 – $19.00
Fundamentals
Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle Ea...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$5.29B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
1.00
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
12.35%
Volume
Today's trading volume
5.45M
Recent News
How The Avantor (AVTR) Narrative Is Shifting After Valuation Reset And Execution Concerns
Avantor’s fair value estimate has been reset from US$10.88 to US$9.92, an 8.8% cut that puts a fresh line in the sand for where analysts see the shares settling. Across the Street, recent commentary links similar target moves, including the US$8.50 level tied to an Underweight rating, to questions about market share and management’s ability to execute. As you read on, you will see how these shifting targets shape the evolving Avantor story and what to watch next. Stay updated as the Fair...
ESAB Corp. (ESAB) Appoints R. Brent Jones as Chief Financial Officer
ESAB Corp. (NYSE:ESAB) is one of the best up and coming stocks with highest upside potential. On April 2, ESAB appointed R. Brent Jones as Chief Financial Officer, effective in early May. Jones, a highly experienced executive with over 30 years of financial leadership, succeeds Kevin Johnson, who is departing to join a private firm. […]
William Blair Keeps Market Perform Rating on Avantor (AVTR) After CFO Departure
Avantor, Inc. (NYSE:AVTR) is one of the 10 Best Medical Stocks to Buy Under $30. On April 1, William Blair reaffirmed its Market Perform rating on Avantor, Inc. (NYSE:AVTR) after the company announced the departure of its Chief Financial Officer, Brent Jones. Jones will leave Avantor, Inc. (NYSE:AVTR) on or before June 24. Despite this […]
Avantor Q1 Earnings & Revenues Beat Estimates, Margins Decline
AVTR benefits from stable Q1 revenues and improving demand trends, though margin pressure and volume softness weigh on profitability.
Avantor Q1 Earnings Call Highlights
Avantor (NYSE:AVTR) said first-quarter 2026 results came in ahead of internal expectations, driven by improved execution in its Bioscience & Medtech Products (BMP) segment and early progress from its “Revival” operational and commercial program. Management reaffirmed full-year guidance and said